Statement by Blue Earth Diagnostics on COVID-19 click here for more information

Latest News From Blue Earth Diagnostics


Blue Earth Diagnostics Expands Oncology Portfolio with Exclusive, Worldwide Licensing of Investigational Radiohybrid PSMA-targeted Agents for Prostate Cancer from Scintomics

– Unique attributes of rhPSMA and approved, commercially available Axumin® (fluciclovine F 18) for PET/CT…

Blue Earth Diagnostics opens new headquarters in Oxford

Expanded facility positions the company for future growth OXFORD, April 12, UK –, 2018 –Blue…

Blue Earth Diagnostics Announces Addition of Axumin® (Fluciclovine F 18) to NCCN Guidelines® for PET Imaging for Suspected Recurrent Prostate Cancer

- NCCN Guidelines aim to improve quality, effectiveness and efficiency of cancer care –  BURLINGTON,…

Blue Earth Diagnostics and GE Healthcare sign UK manufacturing agreement

Agreement marks first step towards full commercial availability of Axumin® (fluciclovine( 18F)) in the UK…

Blue Earth Diagnostics Named as Finalist in First Annual Xconomy Awards

BURLINGTON, Mass. and OXFORD, UK – Aug. 30, 2017 – Blue Earth Diagnostics, a molecular…

Blue Earth Diagnostics shortlisted for “Best Emerging Medtech Company” award

Oxford, UK – August 11, 2017 – Blue Earth Diagnostics, a molecular imaging diagnostics company,…

Blue Earth Diagnostics appoints M2i to manufacture and distribute Axumin™ in Ireland

Oxford, UK –July 27, 2017 – Blue Earth Diagnostics, a molecular imaging diagnostics company and…

Blue Earth Diagnostics joins the British Institute of Radiology

OXFORD, UK – June 28, 2017 - Blue Earth Diagnostics has joined the British Institute…